Perioperative and long-term outcome of en-bloc arterial resection in pancreatic surgery

Georg Wiltberger*, Marcel den Dulk, Jan Bednarsch, Zoltan Czigany, Sven A Lang, Anne Andert, Andreas Lamberzt, Lara R Heij, Judith de Vos-Geelen, Martijn W J Stommel, Ronald M van Dam, Cornelis Dejong, Florian Ulmer, Ulf P Neumann

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Pancreatic tumors are frequently diagnosed in a locally advanced stage with poor prognosis if untreated. This study assesses the safety and oncological outcomes of pancreatic surgery with arterial en-bloc resection.

METHODS: We retrospectively reviewed a prospectively maintained database of patients who underwent a pancreatic resection with arterial resection between 2011 and 2020. Univariable analyses were used to assess prognostic factors for survival.

RESULTS: Forty consecutive patients (22 female; 18 male) undergoing arterial resections were included. Surgical procedures consisted of 19 pancreatoduodenectomies (PD, 48%), 16 distal splenopancreatectomy (DSP, 40%), and 5 total pancreatectomies (TP, 12%). Arterial resection included hepatic arteries (HA, N = 23), coeliac trunk (TC, N = 15) and superior mesenteric artery (SMA, N = 2). Neoadjuvant therapy was applied in 22 patients (58%). Major complications after surgery were observed in 15% of cases. 90-day mortality was 5%. Median disease-free survival and median overall survival were for the R0/CRM- group 22.8 months and 27.9 months, 9.5 and 19.8 months for the R0/CRM+ group, and 10.1 and 13.1 months for the R1 group, respectively.

CONCLUSION: In highly selected patients, arterial en-bloc resection can be performed with acceptable mortality and morbidity rates and beneficial oncological outcome.

Original languageEnglish
Pages (from-to)1119-1128
Number of pages10
JournalHPB
Volume24
Issue number7
Early online date14 Dec 2021
DOIs
Publication statusPublished - Jul 2022

Keywords

  • INTERNATIONAL STUDY-GROUP
  • CONSENSUS STATEMENT
  • PANCREATICODUODENECTOMY
  • CANCER
  • DEFINITION
  • FOLFIRINOX
  • COMPLICATIONS
  • GEMCITABINE

Cite this